Head-to-head evidence
dulaglutide vs semaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT07570810 (registry estimate)
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2030 · NCT07282041 (registry estimate)
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT04560998 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial in nearly 800 people measured walking distance on a standardized treadmill test, a direct functional outcome for peripheral artery disease, and found a statistically significant improvement with semaglutide over placebo.
Next expected readout: September 2028 · NCT07617155 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · semaglutide's landscape